Who Paid My Doc
Daniel Elgut
Podiatrist, Foot & Ankle Surgery Royal Palm Beach, FL Doctor of Podiatric Medicine
NPI 1215354352 CMS profile 4220591
11412 Okeechobee Blvd, Royal Palm Beach, FL 33411
General payments
$72,571
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Elgut of Royal Palm Beach, FL is reported in the CMS Open Payments database as having received $72,571 across 280 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,249 | 22 | |
| 2024 | General | $1,563 | 28 | |
| 2023 | General | $4,067 | 24 | |
| 2022 | General | $4,488 | 60 | |
| 2021 | General | $14,280 | 66 | |
| 2020 | General | $32,114 | 21 | |
| 2019 | General | $14,810 | 59 |
Beside peers
- Daniel Elgut
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to Daniel Elgut were reported at $1,249. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | Daniel Elgut | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $14,810 | $389 | $118–$1,406 | $163 |
| 2020 | $32,114 | $191 | $62–$691 | $114 |
| 2021 | $14,280 | $329 | $104–$1,341 | $132 |
| 2022 | $4,488 | $419 | $125–$1,611 | $149 |
| 2023 | $4,067 | $377 | $128–$1,164 | $160 |
| 2024 | $1,563 | $394 | $134–$1,168 | $164 |
| 2025 | $1,249 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
348
Drug cost
$6,169
Branded share of claims
15.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 11 | $3,699 | |
| Cephalexin | Generic | 49 | $519 | |
| Gabapentin | Generic | 92 | $355 | |
| Methylprednisolone | Generic | 47 | $265 | |
| Ciclopirox | Generic | 14 | $258 | |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | Brand | 23 | $252 | |
| Celecoxib | Generic | 16 | $246 | |
| Mupirocin | Generic | 23 | $198 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 21 | $146 | |
| Doxycycline Hyclate | Generic | 26 | $137 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 65 billing codesPaid by Medicare
$424,988
Medicare patients
704
Services billed
3,415
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Diabetes | 38% | |
| Ischemic heart disease | 38% | |
| Chronic kidney disease | 36% | |
| Depression | 26% | |
| Atrial fibrillation | 24% | |
| Heart failure | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 30 | 40 | $215 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 60 | 308 | $31 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 89 | 124 | $11 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
280 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in Florida
Shayne Jensen
Podiatrist, Foot & Ankle Surgery · Panama City, FL
Thomas Roukis
Podiatrist, Foot & Ankle Surgery · Orlando, FL
Craig Breslauer
Podiatrist, Foot & Ankle Surgery · Stuart, FL
Amber Shane
Podiatrist, Foot & Ankle Surgery · Orlando, FL
Jonathan Blum
Podiatrist, Foot & Ankle Surgery · Kissimmee, FL
Mario Cala
Podiatrist, Foot & Ankle Surgery · Hialeah, FL
Related records
Podiatrist, Foot & Ankle Surgery in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.